Skip to main content
Erschienen in: Surgery Today 9/2014

01.09.2014 | Original Article

Outcome of sentinel lymph node biopsy in breast cancer using dye alone: a single center review with a median follow-up of 5 years

verfasst von: Yoshinari Ogawa, Katsumi Ikeda, Kana Ogisawa, Shinya Tokunaga, Hiroko Fukushima, Takeshi Inoue, Yoshihiro Mori, Akiko Tachimori, Toru Inoue, Yukio Nishiguchi

Erschienen in: Surgery Today | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Various techniques are used for sentinel lymph node biopsy (SLNB) in breast cancer. While subareolar injection with dye alone is a relatively easy method, few studies have reported the outcome with a follow-up period. This study presents our results of SLNB using dye alone.

Methods

Between November 2002 and December 2010, 701 patients with breast cancer underwent SLNB using subareolar injection of indocyanine green or indigo carmine. Sentinel lymph node (SLN)-negative patients were followed without axillary lymph node dissection (ALND).

Results

SLNs were detected in 654 of 701 patients (93.3 %), and the rate increased to 98.1 % over the course of the study. The mean number of SLNs removed was 1.5. There was no significant difference in the detection rate between two dyes. No adverse events resulted from the injection of dyes. Of the 654 patients, 136 (20.8 %) had SLN metastasis. Five hundred patients were followed without ALND. Thirty-six patients experienced disease relapse during a median follow-up of 60 months. Thirteen patients (2.6 %) had regional lymph node relapse, and eight of them could undergo salvage lymph node dissection. The 5-year disease-free and overall survival rates were 92.4 and 96.1 %, respectively.

Conclusion

SLNB using subareolar injection with dye alone was safe and feasible even after a long follow-up.
Literatur
1.
Zurück zum Zitat Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595–600.PubMedCrossRef Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595–600.PubMedCrossRef
2.
Zurück zum Zitat Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomized phase 3 trial. Lancet Oncol. 2010;11:927–33.PubMedCentralPubMedCrossRef Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomized phase 3 trial. Lancet Oncol. 2010;11:927–33.PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Zovagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, et al. A randomized clinical trial on sentinel node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008;247:207–13.CrossRef Zovagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, et al. A randomized clinical trial on sentinel node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008;247:207–13.CrossRef
4.
Zurück zum Zitat Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13:491–500.PubMedCrossRef Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13:491–500.PubMedCrossRef
5.
Zurück zum Zitat Sasada T, Murakami S, Kataoka T, Ohara M, Ozaki S, Okada M, et al. Memorial Sloan-Kettering Cancer Center Nomogram to predict the risk of non-sentinel lymph node metastasis in Japanese breast cancer patients. Surg Today. 2012;42:245–9.PubMedCrossRef Sasada T, Murakami S, Kataoka T, Ohara M, Ozaki S, Okada M, et al. Memorial Sloan-Kettering Cancer Center Nomogram to predict the risk of non-sentinel lymph node metastasis in Japanese breast cancer patients. Surg Today. 2012;42:245–9.PubMedCrossRef
6.
Zurück zum Zitat Tanaka S, Sato N, Fujioka H, Takahashi Y, Kimura K, Iwamoto M. Validation of online calculators to predict the non-sentinel lymph node status in sentinel lymph node-positive breast cancer patients. Surg Today. 2013;43:163–70.PubMedCrossRef Tanaka S, Sato N, Fujioka H, Takahashi Y, Kimura K, Iwamoto M. Validation of online calculators to predict the non-sentinel lymph node status in sentinel lymph node-positive breast cancer patients. Surg Today. 2013;43:163–70.PubMedCrossRef
7.
Zurück zum Zitat Kern KA, Rosenberg RJ. Prospective lymphoscintigraphy during lymphatic mapping for breast cancer: improved sentinel node imaging using subareolar injection of technetium 99m sulfur colloid. J Am Coll Surg. 2000;191:479–89.PubMedCrossRef Kern KA, Rosenberg RJ. Prospective lymphoscintigraphy during lymphatic mapping for breast cancer: improved sentinel node imaging using subareolar injection of technetium 99m sulfur colloid. J Am Coll Surg. 2000;191:479–89.PubMedCrossRef
8.
Zurück zum Zitat Povoski SP, Olsen JO, Young DC, Clarke J, Burak WE, Walker MJ, et al. Prospective randomized clinical trial comparing intradermal, intraparenchymal and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol. 2006;13:1412–21.PubMedCrossRef Povoski SP, Olsen JO, Young DC, Clarke J, Burak WE, Walker MJ, et al. Prospective randomized clinical trial comparing intradermal, intraparenchymal and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol. 2006;13:1412–21.PubMedCrossRef
9.
Zurück zum Zitat Halsell JT, Smith JR, Bentlage CR, Park OK, Humphreys JW Jr. Lymphatic drainage of the breast demonstrated by vital dye staining and radiography. Ann Surg. 1965;162:221–6.PubMedCentralPubMedCrossRef Halsell JT, Smith JR, Bentlage CR, Park OK, Humphreys JW Jr. Lymphatic drainage of the breast demonstrated by vital dye staining and radiography. Ann Surg. 1965;162:221–6.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelly MC, Ye W, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000;18:2553–9.PubMed Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelly MC, Ye W, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000;18:2553–9.PubMed
11.
Zurück zum Zitat Hirche C, Murawa D, Mohr Z, Kneif S, Hünerbein M. ICG-fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer. Breast Cancer Res Treat. 2010;121:373–8.PubMedCrossRef Hirche C, Murawa D, Mohr Z, Kneif S, Hünerbein M. ICG-fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer. Breast Cancer Res Treat. 2010;121:373–8.PubMedCrossRef
12.
Zurück zum Zitat Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–44.PubMedCrossRef Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–44.PubMedCrossRef
13.
Zurück zum Zitat Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98:599–609.PubMedCrossRef Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98:599–609.PubMedCrossRef
14.
15.
Zurück zum Zitat Haigh PI, Hansen NM, Qi K, Giuliano AE. Biopsy method and excision volume do not affect success rate of subsequent sentinel node dissection in breast cancer. Ann Surg Oncol. 2000;7:21–7.PubMedCrossRef Haigh PI, Hansen NM, Qi K, Giuliano AE. Biopsy method and excision volume do not affect success rate of subsequent sentinel node dissection in breast cancer. Ann Surg Oncol. 2000;7:21–7.PubMedCrossRef
16.
Zurück zum Zitat Kaklamanos IG, Birbas K, Syrigos K, Bonatsos VG, Bonatsos G. Prospective comparison of peritumoral and subareolar injection of blue dye alone, for identification of sentinel lymph nodes in patients with early stage breast cancer. J Surg Oncol. 2011;104:37–40.PubMedCrossRef Kaklamanos IG, Birbas K, Syrigos K, Bonatsos VG, Bonatsos G. Prospective comparison of peritumoral and subareolar injection of blue dye alone, for identification of sentinel lymph nodes in patients with early stage breast cancer. J Surg Oncol. 2011;104:37–40.PubMedCrossRef
17.
Zurück zum Zitat Kim T, Giuliano AE, Lyman GH. SLymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a meta analysis. Cancer. 2006;106:4–16.PubMedCrossRef Kim T, Giuliano AE, Lyman GH. SLymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a meta analysis. Cancer. 2006;106:4–16.PubMedCrossRef
18.
Zurück zum Zitat Wong SL, Edwards MJ, Chao C, Tuttle TM, Noyes RD, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg. 2001;192:684–9.PubMedCrossRef Wong SL, Edwards MJ, Chao C, Tuttle TM, Noyes RD, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg. 2001;192:684–9.PubMedCrossRef
19.
Zurück zum Zitat Wang M, Zhou W, Zhao Y, Xia T, Zha X, Ding Q, et al. A novel finding of sentinel lymphatic channels in early stage breast cancer patients: which may influence detection rate and false-negative rate of sentinel lymph node biopsy. PLoS ONE. 2012;7:e51226.PubMedCentralPubMedCrossRef Wang M, Zhou W, Zhao Y, Xia T, Zha X, Ding Q, et al. A novel finding of sentinel lymphatic channels in early stage breast cancer patients: which may influence detection rate and false-negative rate of sentinel lymph node biopsy. PLoS ONE. 2012;7:e51226.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Kapoor NS, Sim MS, Lin J, Giuliano AE. Long-term outcome of patients managed with sentinel lymph node biopsy alone for node-negative breast cancer. Arch Surg. 2012;147:1047–52.PubMedCrossRef Kapoor NS, Sim MS, Lin J, Giuliano AE. Long-term outcome of patients managed with sentinel lymph node biopsy alone for node-negative breast cancer. Arch Surg. 2012;147:1047–52.PubMedCrossRef
21.
Zurück zum Zitat van Wely BJ, van den Wildenberg FJ, Gobardham, P van Dalen T, Borel Rinkes IH, Theunissen EB, et al. Axillary recurrences after sentinel lymph node biopsy: a multicentre analysis and follow-up of sentinel lymph node negative breast cancer patients. J Cancer Surg. 2012;38:925–31. van Wely BJ, van den Wildenberg FJ, Gobardham, P van Dalen T, Borel Rinkes IH, Theunissen EB, et al. Axillary recurrences after sentinel lymph node biopsy: a multicentre analysis and follow-up of sentinel lymph node negative breast cancer patients. J Cancer Surg. 2012;38:925–31.
22.
Zurück zum Zitat de Kenter AY, Menke-Pluymers MM, Wouters MW, Burgmans I, van Geel AN, Eggermont AM. 5-year follow-up of sentinel node negative breast cancer patients. Euro J Surg Oncol. 2006;32:282–6.CrossRef de Kenter AY, Menke-Pluymers MM, Wouters MW, Burgmans I, van Geel AN, Eggermont AM. 5-year follow-up of sentinel node negative breast cancer patients. Euro J Surg Oncol. 2006;32:282–6.CrossRef
23.
Zurück zum Zitat Chua B, Ung O, Boyages J. Competing consideration in regional nodal treatment for early breast cancer. Breast J. 2002;8:15–22.PubMedCrossRef Chua B, Ung O, Boyages J. Competing consideration in regional nodal treatment for early breast cancer. Breast J. 2002;8:15–22.PubMedCrossRef
24.
Zurück zum Zitat Louis-Sylvestre C, Clough K, Asselain B, Vicoq JR, Salmon RJ, Campana F, et al. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol. 2004;22:97–101.PubMedCrossRef Louis-Sylvestre C, Clough K, Asselain B, Vicoq JR, Salmon RJ, Campana F, et al. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol. 2004;22:97–101.PubMedCrossRef
25.
Zurück zum Zitat Kelley LM, Holmes DR. Tracer agents for the detection of sentinel lymph nodes in breast cancer: current concerns and directions for the future. J Surg Oncol. 2011;104:91–6.PubMedCrossRef Kelley LM, Holmes DR. Tracer agents for the detection of sentinel lymph nodes in breast cancer: current concerns and directions for the future. J Surg Oncol. 2011;104:91–6.PubMedCrossRef
26.
Zurück zum Zitat Reyes FJ, Noelck MB, Valentino C, Grasso-LeBeau L, Lang JE. Complication of methylene blue dye in breast surgery: case reports and review of the literature. J Cancer. 2011;2:20–5.PubMedCentralCrossRef Reyes FJ, Noelck MB, Valentino C, Grasso-LeBeau L, Lang JE. Complication of methylene blue dye in breast surgery: case reports and review of the literature. J Cancer. 2011;2:20–5.PubMedCentralCrossRef
27.
Zurück zum Zitat Del Bianco P, Zavagno G, Burelli P, Scalco G, Barutta L, Carraro P, et al. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomized clinical trial. Euro J Surg Oncol. 2008;34:508–13.CrossRef Del Bianco P, Zavagno G, Burelli P, Scalco G, Barutta L, Carraro P, et al. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomized clinical trial. Euro J Surg Oncol. 2008;34:508–13.CrossRef
Metadaten
Titel
Outcome of sentinel lymph node biopsy in breast cancer using dye alone: a single center review with a median follow-up of 5 years
verfasst von
Yoshinari Ogawa
Katsumi Ikeda
Kana Ogisawa
Shinya Tokunaga
Hiroko Fukushima
Takeshi Inoue
Yoshihiro Mori
Akiko Tachimori
Toru Inoue
Yukio Nishiguchi
Publikationsdatum
01.09.2014
Verlag
Springer Japan
Erschienen in
Surgery Today / Ausgabe 9/2014
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-013-0728-9

Weitere Artikel der Ausgabe 9/2014

Surgery Today 9/2014 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Frauen bekommen seltener eine intensive Statintherapie

30.04.2024 Statine Nachrichten

Frauen in den Niederlanden erhalten bei vergleichbarem kardiovaskulärem Risiko seltener eine intensive Statintherapie als Männer. Ihre LDL-Zielwerte erreichen sie aber fast ähnlich oft.

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.